No evidence for TSLP pathway activity in human breast cancer.
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that primes dendritic cells for Th2 induction. It has been implicated in different types of allergic diseases. Recent work suggested that TSLP could play an important role in the tumor microenvironment and influence tumor progression, in particular in breast cancer. In this study we systematically assessed the production of TSLP at the mRNA and protein levels in several human breast cancer cell lines, large-scale public transcriptomics data sets, and primary human breast tumors. We found that TSLP production was marginal, and concerned less than 10% of the tumors, with very low mRNA and protein levels. In most cases TSLP was undetectable and found to be expressed at lower levels in breast cancer as compared to normal breast tissue. Last, we could not detect any functional TSLP receptor (TSLPR) expression neither on hematopoietic cells nor on stromal cells within the primary tumor microenvironment. We conclude that TSLP-TSLPR pathway activity is not significantly detected within human breast cancer. Taken together, these observations do not support TSLP targeting in breast cancer.
U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
Cristina
C
Ghirelli
U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Institut Curie, Paris, France; Statistics and Genome team of the Laboratoire de Mathématiques et Modélisation d'Évry, University of Évry val d'Essonne/UMR CNRS 8071/USC INRA, Evry, France.
Benjamin
B
Sadacca
U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Institut Curie, Paris, France; Department of Surgery, Institut Curie, Paris, France.
Fabien
F
Reyal
U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
Raphaël
R
Zollinger
U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
Paula
P
Michea
U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
Philémon
P
Sirven
U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
Lucia
L
Pattarini
U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
Carolina
C
Martínez-Cingolani
U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
Maude
M
Guillot-Delost
Platform of Investigative Pathology of Biopathology Department, Curie Institute , Paris, France.
André
A
Nicolas
U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
Alix
A
Scholer-Dahirel
U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
Vassili
V
Soumelis
Breast cancer; cytokines; dendritic cells; thymic stromal lymphopoietin; tumor microenvironment